JP2023530997A5 - - Google Patents

Info

Publication number
JP2023530997A5
JP2023530997A5 JP2022578554A JP2022578554A JP2023530997A5 JP 2023530997 A5 JP2023530997 A5 JP 2023530997A5 JP 2022578554 A JP2022578554 A JP 2022578554A JP 2022578554 A JP2022578554 A JP 2022578554A JP 2023530997 A5 JP2023530997 A5 JP 2023530997A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
cdr
sequence identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022578554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530997A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/037920 external-priority patent/WO2021257894A1/en
Publication of JP2023530997A publication Critical patent/JP2023530997A/ja
Publication of JP2023530997A5 publication Critical patent/JP2023530997A5/ja
Pending legal-status Critical Current

Links

JP2022578554A 2020-06-19 2021-06-17 Ｂｓｔ２ロングアイソフォームを標的化する抗ｂｓｔ２抗体 Pending JP2023530997A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063041421P 2020-06-19 2020-06-19
US202063041450P 2020-06-19 2020-06-19
US63/041,450 2020-06-19
US63/041,421 2020-06-19
US202163152811P 2021-02-23 2021-02-23
US63/152,811 2021-02-23
PCT/US2021/037920 WO2021257894A1 (en) 2020-06-19 2021-06-17 Anti-bst2 antibodies targeting bst2 long isoform

Publications (2)

Publication Number Publication Date
JP2023530997A JP2023530997A (ja) 2023-07-20
JP2023530997A5 true JP2023530997A5 (https=) 2024-06-24

Family

ID=79268440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022578554A Pending JP2023530997A (ja) 2020-06-19 2021-06-17 Ｂｓｔ２ロングアイソフォームを標的化する抗ｂｓｔ２抗体

Country Status (4)

Country Link
US (1) US20230235074A1 (https=)
EP (1) EP4168029A4 (https=)
JP (1) JP2023530997A (https=)
WO (1) WO2021257894A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121135899B (zh) * 2025-11-19 2026-03-03 中国医学科学院病原生物学研究所 一种hiv抗性分子及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
AU2005333155B2 (en) * 2005-03-14 2011-11-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies against Hendra and Nipah viruses
WO2008036688A2 (en) * 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
KR20100090258A (ko) * 2007-10-16 2010-08-13 에스비아이 바이오테크 가부시키가이샤 항ｂｓｔ2 항체
US20110311558A1 (en) * 2008-12-01 2011-12-22 The Board Of Regents Of The University Of Texas System Recombinant Bone Marrow Stromal Antigen-2 in the Treatment of Autoimmune Diseases
US9540449B2 (en) * 2012-08-13 2017-01-10 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
WO2015083791A1 (ja) * 2013-12-04 2015-06-11 国立研究開発法人理化学研究所 肺癌の検出方法および検出キット
CA2932424C (en) * 2013-12-06 2023-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
US20170335281A1 (en) * 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
US10544201B2 (en) * 2014-07-31 2020-01-28 Cellectis ROR1 specific multi-chain chimeric antigen receptor
JP6783777B2 (ja) * 2015-02-09 2020-11-11 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． 二次感染の予防方法
WO2016179319A1 (en) * 2015-05-04 2016-11-10 Cellerant Therapeutics, Inc. Chimeric antigen receptors with ctla4 signal transduction domains
CN107619443B (zh) * 2016-07-14 2020-08-14 深圳宾德生物技术有限公司 抗人和鼠cd317的单克隆抗体及其制备方法和应用
US10648987B2 (en) * 2017-06-15 2020-05-12 Wayne State University Methods and compositions relating to anti-HcTnT-N69 antibody for detection of cardiac disorders
CN109748964B (zh) * 2017-11-01 2020-11-17 深圳宾德生物技术有限公司 CD317单链抗体317scFv、其编码序列及制备方法和应用
EP3759145A4 (en) * 2018-02-26 2022-03-09 Minerva Biotechnologies Corporation DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES

Similar Documents

Publication Publication Date Title
JP7844558B2 (ja) リンパ球における阻害経路の中和
CN110291109B (zh) 人程序性死亡受体pd-1的单克隆抗体及其片段
JP6767362B2 (ja) リンパ球における阻害経路の中和
AU2020307471A1 (en) Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen
EP4039705A1 (en) Antibody targeting bcma, bispecific antibody, and use thereof
CN109160949B (zh) 一种鼠抗人pd-1单克隆抗体及应用
KR20180008571A (ko) 다발성 골수종(mm)의 치료
US20250179187A1 (en) Anti pd-l2 antibody
US20250179168A1 (en) Materials and methods for treating stress-related disorders and cancer
JP2025510642A5 (https=)
JP2023521228A (ja) 癌の併用療法
CN118339187A (zh) 抗pd-1抗体及其用途
JP2023530997A5 (https=)
EP4483899A1 (en) Medicine comprising combination of anti-mutant-calr antibody and another drug
TW202005983A (zh) 抗-人類pd-l1之抗體及其用途
CN120282984A (zh) 抗人类pd-l1抗体及其用途
US20230192833A1 (en) New anti-VEGFC antibodies and uses thereof
JP2024502670A5 (https=)
EP4428159A1 (en) Melanoma targeting human antibodies and therapeutic uses thereof
WO2024149224A1 (zh) Ccr8抗体的应用
EP4712977A1 (en) Uses of t cell engaging proteins in the treatment of cancer
HK40121119A (en) Medicine comprising combination of anti-mutant-calr antibody and another drug
CN120092018A (zh) 使用抗ctla4抗体治疗癌症的方法
TW202612728A (zh) 使用靶向表現her2之腫瘤之三特異性結合蛋白治療癌症之方法
CN116848144A (zh) 抗pd-l1抗体及其用途